Zhitong Finance App News, Shisi Pharmaceutical Group (02005.HK) announced that the Group's ziprasidone hydrochloride has been approved by the China National Drug Administration for registration as an active ingredient for use in marketed formulations. Ziprasidone hydrochloride is a novel atypical broad-spectrum antipsychotic. It is a second-generation antipsychotic drug, mainly used to treat schizophrenia.

Zhitongcaijing · 1d ago
Zhitong Finance App News, Shisi Pharmaceutical Group (02005.HK) announced that the Group's ziprasidone hydrochloride has been approved by the China National Drug Administration for registration as an active ingredient for use in marketed formulations. Ziprasidone hydrochloride is a novel atypical broad-spectrum antipsychotic. It is a second-generation antipsychotic drug, mainly used to treat schizophrenia.